LISINOPRIL TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

LISINOPRIL (LISINOPRIL DIHYDRATE)

제공처:

COBALT PHARMACEUTICALS COMPANY

ATC 코드:

C09AA03

INN (International Name):

LISINOPRIL

복용량:

20MG

약제 형태:

TABLET

구성:

LISINOPRIL (LISINOPRIL DIHYDRATE) 20MG

관리 경로:

ORAL

패키지 단위:

30/100/500

처방전 유형:

Prescription

치료 영역:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

제품 요약:

Active ingredient group (AIG) number: 0121550002; AHFS:

승인 상태:

CANCELLED PRE MARKET

승인 날짜:

2017-09-01

제품 특성 요약

______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 1 of 44 _
_ _
_ _
PRODUCT MONOGRAPH
PR
LISINOPRIL
Lisinopril Tablets, USP
5 mg, 10 mg and 20 mg
(of Lisinopril as Lisinopril Dihydrate)
Angiotensin Converting Enzyme Inhibitor
Cobalt Pharmaceuticals Company
6500 Kitimat Road
Mississauga, Ontario
Canada, L5N 2B8
CONTROL NUMBER: 172480
Date of Revision:
March 4, 2014
______________________________________________________________________________________________
_
_LISINOPRIL (Lisinopril Tablets, USP) 5 mg, 10 mg and 20 mg _
_Page 2 of 44 _
_ _
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
5
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
17
DOSAGE AND ADMINISTRATION
.....................................................................................
20
OVERDOSAGE
.......................................................................................................................
23
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 23
STORAGE AND STABILITY
.................................................................................................
26
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................